Cyril Allouche, Principal Accounting Officer at Revance Therapeutics, Inc. (RVNC), sold 625 shares at $17.77 ($11K) on 2019-01-22, disclosed to the SEC on 2019-01-23.
Scheduled sale ($11k) by Principal Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RVNC | SELL | 2018-11-21 | $10K | — | Filing → |
| RVNC | SELL | 2018-11-09 | $104K | — | Filing → |
| RVNC | SELL | 2018-07-06 | $11K | — | Filing → |